| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
507,989 |
143,419 |
$32.86M |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
507,554 |
143,336 |
$10.71M |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
524,120 |
149,626 |
$7.16M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
40,526 |
35,689 |
$2.41M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
9,806 |
9,625 |
$740K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
16,294 |
12,172 |
$495K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
8,729 |
5,256 |
$426K |
| S9083 |
Global fee urgent care centers |
3,958 |
1,209 |
$301K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
6,327 |
6,141 |
$298K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
3,439 |
3,189 |
$292K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
28,073 |
13,195 |
$277K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
9,037 |
8,313 |
$216K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
8,925 |
5,503 |
$120K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
16,979 |
16,155 |
$86K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
489 |
484 |
$53K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,524 |
1,443 |
$30K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
1,483 |
1,405 |
$25K |
| 87070 |
|
3,598 |
3,349 |
$21K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
936 |
872 |
$18K |
| 87184 |
|
3,529 |
3,279 |
$17K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
653 |
646 |
$14K |
| 93000 |
|
864 |
847 |
$12K |
| 36415 |
Collection of venous blood by venipuncture |
5,134 |
4,875 |
$9K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
150 |
149 |
$7K |
| 99000 |
|
15,478 |
7,469 |
$7K |
| 81000 |
|
1,816 |
1,760 |
$5K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
40 |
40 |
$5K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
89 |
87 |
$4K |
| 92587 |
|
172 |
170 |
$4K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
61 |
61 |
$3K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
169 |
168 |
$2K |
| 90686 |
|
118 |
118 |
$2K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
27 |
27 |
$2K |
| 99050 |
|
752 |
713 |
$2K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
15 |
15 |
$752.25 |
| 81025 |
|
167 |
165 |
$713.28 |
| H0033 |
Oral medication administration, direct observation |
13 |
13 |
$318.65 |
| 99195 |
|
15 |
15 |
$156.69 |
| 99051 |
|
13 |
12 |
$91.91 |
| 94760 |
|
207 |
198 |
$68.48 |
| 85018 |
|
69 |
69 |
$66.93 |
| 2010F |
|
354 |
328 |
$0.00 |